Printer Friendly
The Free Library
14,530,286 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kyowa Hakko Kogyo to Release Plant-derived Glucosamine for Commercial Use in September.


Tokyo, Japan, Aug 12, 2005 - (JCNN JCNN Japan Corporate News Network ) - Kyowa Hakko Kogyo (TSE See Tokyo Stock Exchange.

TSE

1. See Tokyo Stock Exchange (TSE).

2. See Toronto Stock Exchange (TSE).
: 4151) will launch Hakko (Fermented) Glucosamine glucosamine /glu·co·sa·mine/ (gloo-ko´sah-men) an amino derivative of glucose, occurring in glycosaminoglycans and a variety of complex polysaccharides such as blood group substances.  K, plant-derived glucosamine powder for commercial use, on September 2.

The new product, which is made of plants and fermented by chitin, a kind of microorganism microorganism /mi·cro·or·gan·ism/ (-or´gah-nizm) a microscopic organism; those of medical interest include bacteria, fungi, and protozoa. , is odor-free, white powder used as a food additive.

The new product is the first such powder that has been derived from plants.

Kyowa Hakko Kogyo will import an intermediate material from a US manufacturer and refine it as an end product. Since the new product is based on plants instead of shellfish, a raw material conventionally used, a stable supply is expected.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 12, 2005
Words:121
Previous Article:J-POWER to Purchase 2.82 Million Ton of Emission Credit From CDM in Brazil.
Next Article:Otsuka Pharmaceutical to Introduce New Dosage Form for Its bronchodilator Meptin.



Related Articles
Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.
Kyowa Hakko Chemical to Increase Production Capacity of 2-Ethyl Hexanoic Acid.
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Kyowa Hakko Kogyo to Introduce Self-Injectable Drug for Treating Parkinson's Disease from Britannia Pharmaceuticals.
Kyowa Hakko Kogyo Begins Operations at New Plant in China.
Kyowa Hakko Kogyo Completes Overseas Phase III Clinical Trials for KW-6002, Anti-Parkinson's Disease Agent.
Meiji Dairies, Kyowa Hakko Kogyo Receive Approval for MRI Digestive Tract Contrast Medium BOTHDEL.
Kyowa Hakko Kogyo to Expand Its Fuji Plant and Accelerate R&D for Antibody Drugs.
Kyowa Hakko Develops World's First Fermentation-based Commercial Production Method for L-Tyrosine.
Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles